News Releases
Jul 21, 2021
Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , July 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the novel mechanism of action (MOA) of
Jul 07, 2021
Merus to Participate in William Blair's Biotech Focus Conference 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., Chief Executive
Jun 04, 2021
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date - Encouraging early clinical activity observed, with confirmed responses in 5 of 12 patients with pancreatic cancer (42%) and in 13 of 45 patients across
May 26, 2021
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., Chief Executive
May 19, 2021
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
- 51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021 , data cutoff date - Encouraging early clinical activity observed, with confirmed partial responses in 4 of 10 patients with pancreatic cancer (40%) and in 9 of 33
May 13, 2021
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced new collaborations in Israel , Italy and Spain
May 11, 2021
Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg , M.D., Chief Executive Officer
May 06, 2021
Merus Announces Financial Results for the First Quarter and Provides Business Update
Clinical data update on zenocutuzumab selected for oral presentation at ASCO MCLA-145 clinical update planned for 2H21 MCLA-129 first patient dosed in phase 1/2 trial Cecile Geuijen, Ph.D., promoted to Chief Scientific Officer UTRECHT, The Netherlands and CAMBRIDGE, Mass.
May 03, 2021
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
Merus’ Fourth Sponsored Bispecific Antibody Currently in Clinical Trials UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 03, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length
Apr 28, 2021
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 28, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the
Mar 16, 2021
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021 Clinical update planned for MCLA-145 in 2H 2021 MCLA-129 expected to enter clinic in the United States in 2021 UTRECHT , The Netherlands and CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Merus N.V.
Mar 10, 2021
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that
Mar 08, 2021
Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 08, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., Chief Executive
Feb 01, 2021
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that Bill Lundberg , M.D., Chief Executive
Jan 21, 2021
Merus Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands , and CAMBRIDGE, Mass. , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an
Jan 19, 2021
Merus N.V. Announces Proposed Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced the launch of a
Jan 19, 2021
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
INDIANAPOLIS and UTRECHT, The Netherlands , Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly , a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research
Jan 12, 2021
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial
UTRECHT, The Netherlands , and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced collaborations with nationwide medical
Jan 11, 2021
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that
Jan 07, 2021
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length
Dec 17, 2020
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
UTRECHT, The Netherlands and STAMFORD, Conn. , Dec. 17, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multi-specific antibodies (Biclonics® and Triclonics TM ), and Sem a 4 , a patient-centered health intelligence company,
Nov 16, 2020
Merus to Present at the Jefferies Virtual London Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief
Nov 09, 2020
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that
Nov 05, 2020
Merus Announces Financial Results for the Third Quarter and Provides Business Update
– Clinical data and program update planned for lead program Zenocutuzumab (“Zeno”) in 2Q 2021 – – MCLA-129 expected to enter clinic in 2021 – UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a
Oct 12, 2020
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
UTRECHT, The Netherlands , and CAMBRIDGE, Mass. , Oct. 12, 2020 (GLOBE NEWSWIRE) -- myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today
Aug 07, 2020
Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference
UTRECHT , The Netherlands, and CAMBRIDGE, Mass. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that Bill Lundberg , M.D., President and Chief
Aug 06, 2020
Merus Announces Financial Results for the Second Quarter and Provides Business Update
– Lead program Zenocutuzumab remains on track – – Dr. Andrew Joe appointed Chief Medical Officer – – Merus extends cash runway into 2H 2022 – UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a
Jul 27, 2020
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S.
Jul 27, 2020
Merus Appoints Andrew Joe, M.D., as Chief Medical Officer
Dr. Joe brings seasoned research and development leadership and deep expertise in the clinical development of immuno-oncology, antibody, and targeted therapies for cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V.
Jul 13, 2020
Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients
Caris to provide DNA and RNA molecular testing to support patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial UTRECHT, The Netherlands and CAMBRIDGE, Mass. and IRVING, Texas , July 13, 2020 (GLOBE NEWSWIRE) -- Merus N.V.
Jun 01, 2020
Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that
May 14, 2020
Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates
– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers – – MCLA-117 demonstrates limited clinical activity in Phase 1 trial – – Extensive panel of novel CD3 bispecific antibodies provides important insights and
May 11, 2020
Merus Announces Financial Results for the First Quarter and Provides Business Update
MCLA-128, zenocutuzumab, Phase 1/2 eNRGy trial remains on track MCLA-117 program update to be presented at upcoming medical meeting Anand Mehra , M.D. to succeed Russell Greig , Ph.D. as Chairman and Paolo Pucci Nominated for Appointment to Merus Board of Directors UTRECHT, The Netherlands and
Mar 12, 2020
Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 12, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics TM ), today announced financial results
Dec 16, 2019
Merus Announces Chief Executive Officer Transition
— Bill Lundberg , M.D., nominated for appointment as Chief Executive Officer — — Ton Logtenberg, Ph.D., to step down after 16 years of leadership — — Transition to occur December 31, 2019 — UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Merus N.V.
Nov 12, 2019
Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced financial results for the third
Nov 05, 2019
Merus Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands , and CAMBRIDGE, Mass. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offering price of
Nov 04, 2019
Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics ® , today announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shares.
Oct 27, 2019
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Of nine patients enrolled across the MCLA-128 Early Access Program
Oct 25, 2019
Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Company to host investor call on Monday, October 28th at 8:00AM ET UTRECHT, The Netherlands and BOSTON , Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing Biclonics®, innovative full-length
Aug 19, 2019
Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update
UTRECHT, The Netherlands , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the
Jun 03, 2019
Merus to Present at the Jefferies 2019 Healthcare Conference
UTRECHT, Netherlands , June 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,
May 30, 2019
Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update
UTRECHT, The Netherlands , May 30, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the
May 23, 2019
Merus Announces 2019 Annual General Meeting of Shareholders
UTRECHT, The Netherlands , May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General
May 20, 2019
Merus to Present at the RBC Capital Markets 2019 Healthcare Conference
UTRECHT, Netherlands , May 20, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,
May 09, 2019
Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors
UTRECHT, Netherlands , May 09, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the first patient has been treated in its Phase 1 trial evaluating
Apr 03, 2019
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update
Multiple Updates from Biclonics® Clinical Trials Expected in 2019 UTRECHT, The Netherlands , April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics ® , innovative full-length human
Apr 01, 2019
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
CD137 and PD-L1 bispecific antibody with context-dependent T cell activation UTRECHT, Netherlands , April 01, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human
Mar 11, 2019
Merus to Present at the Cowen & Co. 39th Annual Health Care Conference
UTRECHT, Netherlands , March 11, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,
Feb 07, 2019
Merus to Participate in Guggenheim Healthcare Talks Idea Forum
UTRECHT, Netherlands, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Mark Throsby, Ph.D., Executive Vice President and Chief Scientific
Jan 07, 2019
Merus Announces IND Clearance for MCLA-145
MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137 UTRECHT, The Netherlands, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today
Jan 02, 2019
Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China
Merus to retain all global rights outside of China Betta Pharmaceuticals to fund global IND-enabling activities UTRECHT, the Netherlands, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing
Dec 27, 2018
Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update
Clinical milestones for four lead Biclonics ® programs expected in 2019 Cash expected to be sufficient to fund operations into the second quarter of 2021 UTRECHT, The Netherlands, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage
Dec 20, 2018
Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals
Merus and Regeneron to cross-license patents relating to certain antibody generation platform technologies Regeneron to purchase $15 million of Merus common shares UTRECHT, The Netherlands, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company
Nov 08, 2018
Merus to Present at the Jefferies 2018 London Healthcare Conference
UTRECHT, The Netherlands, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., President and Chief Executive Officer of Merus, will
Sep 27, 2018
Merus to Present at the Cantor Fitzgerald Global Healthcare Conference
UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President, Chief Business Officer and Head of
Sep 27, 2018
Merus Strengthens Team with Key Appointments
Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Peter B. Silverman, J.D., appointed EVP, General Counsel Jillian Connell joins as VP, Investor Relations and Corporate Communications UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a
Aug 30, 2018
Merus to Participate in Citi’s 13th Annual Biotech Conference
UTRECHT, The Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., President and Chief Executive Officer, will participate in
Aug 22, 2018
Merus Announces Formation of a Scientific Advisory Board
- Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of Bispecific Antibodies - UTRECHT, The Netherlands, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody
Aug 10, 2018
Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results
MCLA-128 Phase 1/2 clinical data from the gastric cancer cohort will be presented at the European Society for Medical Oncology Congress in October 2018 UTRECHT, The Netherlands, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage
Aug 07, 2018
Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018
UTRECHT, The Netherlands, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President and Chief Business Officer, will present
Jul 26, 2018
Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018
- Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors - - MCLA-128’s unique mechanism of action published in the scientific journal Cancer Cell - UTRECHT, The Netherlands, July 26, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or
Jul 05, 2018
Merus Announces Annual Meeting of Shareholders
UTRECHT, The Netherlands, July 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20,
May 31, 2018
Merus to Present at the Jefferies 2018 Healthcare Conference
UTRECHT, The Netherlands , May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that Hui Liu , Ph.D., Executive Vice President and Chief Business Officer, will
May 24, 2018
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors
- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands , May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been
May 15, 2018
Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell
UTRECHT, The Netherlands , May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the unique mechanism of action (MOA) of MCLA-128, the Company’s most-advanced
Apr 26, 2018
Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017
- Phase 2 combination trial in two metastatic breast cancer (MBC) populations initiated for Merus’ most advanced bispecific antibody candidate, MCLA-128 - - Strategic collaboration announced with Simcere Pharmaceutical Group for multiple bispecific antibodies; expanded collaboration with Ono
Apr 19, 2018
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018
Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands , April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the
Mar 20, 2018
Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer
UTRECHT, The Netherlands , March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), and the Vall d’Hebron Institute of Oncology (VHIO), a leading comprehensive cancer center of
Mar 14, 2018
Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases
UTRECHT, The Netherlands , March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ono Pharmaceutical Co. , LTD. ( Osaka, Japan , ‘Ono’) has exercised its option
Mar 13, 2018
Merus’ Intellectual Property Portfolio Expands with Two New Patents
Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® Technology for Efficient Generation of Biclonics® Candidates UTRECHT, The Netherlands , March 13, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific
Mar 06, 2018
Merus to Present at the Cowen & Co. 38th Annual Health Care Conference
UTRECHT, The Netherlands , March 06, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview
Feb 14, 2018
Merus Announces $55.8 Million Private Placement Offering of Common Stock
UTRECHT, The Netherlands , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that it has agreed to sell 3.1 million shares of its common shares to Biotechnology
Feb 05, 2018
Merus Announces Participation in Four Investor Conferences in February 2018
UTRECHT, The Netherlands , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company’s management will participate at four upcoming investor conferences
Jan 26, 2018
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
Combination trial to evaluate MCLA-128 in HER2-positive and hormone receptor-positive/HER2-low metastatic breast cancer patients UTRECHT, the Netherlands , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody
Jan 08, 2018
Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies
UTRECHT, Netherlands and NANJING , China , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop and commercialize in China three bispecific antibodies utilizing Merus’
Jan 04, 2018
Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs
- IND submitted to U.S. FDA for MCLA-117 in AML - - First CTA approval for MCLA-158 received in European country - UTRECHT, The Netherlands , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics
Jan 02, 2018
Merus to Present at the 36th Annual J.P. Morgan Healthcare Conference
UTRECHT, The Netherlands , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 36 th
Dec 27, 2017
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
UTRECHT, The Netherlands , Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that the United States Court of Appeals for the Federal Circuit denied Regeneron
Nov 30, 2017
Merus Announces Third Quarter 2017 Financial Results and Clinical Highlights
UTRECHT, The Netherlands , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced financial results for the third quarter ended September 30, 2017 and provided a
Nov 09, 2017
Merus to Present at the Jefferies London Healthcare Conference
UTRECHT, The Netherlands , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday,
Oct 10, 2017
Merus to Participate in the BIO Investor Forum
UTRECHT, The Netherlands , Oct. 10, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will be participating in the 2017 BIO Investor
Sep 20, 2017
Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology
UTRECHT, The Netherlands , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Merus (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, announced today that it has added to its deep intellectual property portfolio two new U.S.
Sep 19, 2017
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress
UTRECHT, The Netherlands , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced financial results for the second quarter ended June 30, 2017 and provided a
Aug 30, 2017
Merus to Participate in Two Investor Conferences in September 2017
UTRECHT, The Netherlands , Aug. 30, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will participate at two upcoming
Aug 09, 2017
Merus to Present at the 2017 Wedbush PacGrow Healthcare Conference
UTRECHT, The Netherlands , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview
Jul 28, 2017
U.S. Court of Appeals for the Federal Circuit Affirms Merus’ Inequitable Conduct Claim Against Regeneron
UTRECHT, The Netherlands , July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the trial court’s
Jul 11, 2017
Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results
Balance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover and develop bispecific antibodies Based on single agent activity in the MCLA-128 Phase 1/2 clinical trial, Phase 2
Jul 06, 2017
Merus to Report First Quarter 2017 Financial & Mid-Year Operating Results on July 11, 2017
Conference call and webcast scheduled on 4:30pm ET UTRECHT, The Netherlands , July 06, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the company will provide an
Jun 12, 2017
Merus N.V. to participate in Webcast on Making a name in cancer immunotherapy
Utrecht, The Netherlands— June 2017 —Ton Logtenberg, Founder and Chief Executive Officer of Merus N.V. will participate in a BioPharma Dealmakers webcast, sponsored in part by Merus N.V., featuring three other companies innovating cancer immunotherapy.
Jun 01, 2017
Merus to Present at the Jefferies 2017 Global Healthcare Conference
UTRECHT, The Netherlands , June 01, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the
May 17, 2017
Merus Announces Promising Results from MCLA-128 Phase 1/2 Study in Metastatic Breast Cancer
Results to be presented at the 2017 American Society of Clinical Oncology Annual Meeting Phase 2 clinical trial to be initiated in second half of 2017 exploring two metastatic breast cancer populations: HER2-positive patients and hormone receptor-positive/HER2-low patients UTRECHT, The Netherlands
May 09, 2017
Merus Announces Annual Meeting of Shareholders
UTRECHT, The Netherlands , May 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 24 ,
May 03, 2017
CORRECTING and REPLACING -- Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments
In a release issued April 28, 2017 by Merus N.V. (Nasdaq:MRUS) with the same headline, an error was made such that the figures for the three months ended December 31, 2016 in the “Consolidated Statement of Profit or Loss and Comprehensive Loss” table were incorrect.
Apr 28, 2017
Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments
UTRECHT, The Netherlands , April 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the fourth quarter and full year ended December 31, 2016 and provided a
Apr 20, 2017
Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting
UTRECHT, The Netherlands , April 20, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that data from a Phase 1/2 study of MCLA-128 for the treatment of metastatic breast cancer will be
Mar 16, 2017
Merus Named BioCapital Europe 2017 Company of the Year
Award Recognizes Company’s Substantial Transformation and Breakthroughs Over Past 12 Months UTRECHT, The Netherlands , March 16, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that
Feb 27, 2017
Merus to Present at the Cowen & Co. 37th Annual Health Care Conference
UTRECHT, The Netherlands , Feb. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the Cowen
Feb 09, 2017
Merus to Present at the Leerink Partners 6th Annual Global Healthcare Conference
UTRECHT, The Netherlands , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will participate at the Leerink Partners 6 th
Jan 23, 2017
Merus Announces Closing of Global Strategic Research Collaboration with Incyte to Discover and Develop Bispecific Antibodies
UTRECHT, The Netherlands , Jan. 23, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of its global strategic research collaboration with Incyte Corporation (NASDAQ:INCY)
Jan 05, 2017
Merus and the Institute for Research in Biomedicine (IRB) Barcelona Form Research Collaboration to Develop Bispecific Antibodies Targeting the Tumor Microenvironment
UTRECHT, The Netherlands , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and the Institute for Research in Biomedicine (IRB) Barcelona , a research center devoted to understanding
Dec 21, 2016
Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies
Collaboration designed to leverage Merus ’ Biclonics ® bispecific antibody technology to expand Incyte ’ s discovery capabilities and large-molecule portfolio Incyte to make up-front payment of $120 million and purchase $80 million of Merus common shares; Merus eligible to receive potential
Nov 15, 2016
Merus Announces Favorable Decisions in Europe and Japan for Patents Covering Genetically-Modified Mice for Common Light Chain Human Monoclonal Antibodies
European Patent Office Dismisses Arguments by Regeneron Favorable Rulings Further Strengthen IP Estate in Europe and Japan through 2029 UTRECHT, The Netherlands , Nov. 15, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific
Nov 10, 2016
Merus to Present at the Jefferies London Healthcare Conference
UTRECHT, The Netherlands , Nov. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday,
Nov 09, 2016
Merus N.V. Receives €1.5 Million EUREKA Eurostars Grant with Aquila BioMedical Ltd to Jointly Develop Immunological Assays for Identification of Novel Immunomodulatory Bispecific Antibodies
UTRECHT, The Netherlands and EDINBURGH, UK , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that it has been awarded a €1.5 million EUREKA Eurostars grant (“iMOD-ReACT”)
Nov 07, 2016
Merus Announces Third Quarter 2016 Financial Results and Corporate Developments
UTRECHT, The Netherlands , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the third quarter ended September 30, 2016 and provided a review of recent
Nov 03, 2016
Merus Strengthens Executive Management Team with the Appointment of John Crowley as Chief Financial Officer
Former CFO Shelley Margetson Elevated to Chief Operating Officer UTRECHT, The Netherlands , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of John Crowley as
Oct 26, 2016
Merus Expands Executive Management Team with the Appointment of L. Andres Sirulnik, MD, PhD, as Chief Medical Officer
UTRECHT, The Netherlands , Oct. 26, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of L. Andres Sirulnik , MD, PhD, to the position of Chief Medical Officer, where he
Oct 19, 2016
Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody Candidate for Clinical Development and Extends Partnership with CMC Service Agreement
UTRECHT, The Netherlands , Oct. 19, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company received an undisclosed milestone payment from Ono Pharmaceutical Co., LTD.
Aug 31, 2016
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands , Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences: Ton Logtenberg,
Aug 10, 2016
Merus to Present at the 2016 Wedbush PacGrow Healthcare Conference
UTRECHT, The Netherlands , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday,
Aug 08, 2016
Merus Announces Second Quarter 2016 Financial Results and Reviews Recent Clinical Progress and Corporate Developments
UTRECHT, The Netherlands , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2016 and provided a review of recent
Jul 12, 2016
Merus Announces First Quarter 2016 Financial Results and Highlights Recent Clinical Progress and Corporate Developments
Raises $53.3 Million in Successful Initial Public Offering Doses First Patient in Phase 1/2 Study of MCLA-117 in Patients with AML UTRECHT, The Netherlands, July 12, 2016 (GLOBE NEWSWIRE) -- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics,
Jun 01, 2016
Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology
Bispecific Cancer Antibody Pipeline Optimized by GlymaxX® Manufacturing Technology BERLIN & UTRECHT, The Netherlands , June 01, 2016 (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today jointly announced that Merus has signed a commercial multi-product license
May 31, 2016
Merus N.V. Announces Closing of Partial Exercise of Underwriters' Over-Allotment Option
UTRECHT, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. ("Merus") ( MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of a partial exercise of the over-allotment option by the underwriters of its
May 24, 2016
Merus N.V. Announces Closing of Initial Public Offering
UTRECHT, the Netherlands , May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (“Merus”) (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share. The shares began trading on The NASDAQ Global Market under
May 18, 2016
Merus Announces Pricing of Initial Public Offering
UTRECHT, the Netherlands , May 18, 2016 (GLOBE NEWSWIRE) -- Merus B.V. (“Merus”) today announced the pricing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share, before underwriting discounts and commissions.
May 04, 2016
Merus Announces First Patient Dosed in Phase 1/2 Trial Evaluating Bispecific Antibody Candidate MCLA-117 in Patients with AML
UTRECHT, The Netherlands (GLOBE NEWSWIRE) — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the first patient has been dosed in the Company's Phase 1/2 clinic al trial evaluating MCLA-117 as a potential treatment of
Apr 15, 2016
Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Association for Cancer Research 2016 Annual Meeting
MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activity in Patients with Advanced Solid Tumors UTRECHT, The Netherlands, April 15, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics),
Mar 09, 2016
Merus Announces Issuance of Three U.S. Patents Strengthening its Biclonics® Technology Platform for the Discovery and Manufacturing of Human Bispecific Antibodies
Utrecht, The Netherlands, March 9, 2016 - Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the United States Patent and Trademark Office (USPTO) has issued three patents related to the generation of bispecific
Jan 04, 2016
Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Immuno-oncology Applications
Utrecht, The Netherlands and Villejuif, France, January 4, 2016 — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, today announced entry into a strategic
Dec 16, 2015
Merus Appoints Hui Liu as Chief Business Officer
Novartis Oncology ’ s Former Global Head of Business Development and Licensing Joins Immuno-oncology Biotech Company Utrecht, The Netherlands, December 16, 2015 — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the
Nov 03, 2015
Merus announces final Ruling in inequitable conduct case against Regeneron
Court Further Rules That Regeneron Engaged in Affirmative Egregious Misconduct UTRECHT, The Netherlands, Nov. 3, 2015 (GLOBE NEWSWIRE) — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the U.S.
Aug 26, 2015
Merus enters into € 72.8 million series C financing led by Sofinnova Ventures and Novo A/S
Utrecht, The Netherlands., August 26, 2015 – Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has entered into an agreement with investors for the sale of up to € 72.8 million ($80.5 million) of Series C
Aug 10, 2015
Merus Prevails in Inequitable Conduct Case Against Regeneron
• Court ruling further strengthens Merus’ freedom to operate in using transgenic mice for therapeutic human antibodies Utrecht, The Netherlands, August 10, 2015 — Merus, a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that it won
Jun 01, 2015
Merus appoints Mark Iwicki as President of the Supervisory Board
Utrecht, The Netherlands, June 1, 2015 — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as President of its Supervisory Board. “We welcome Mark as an instrumental addition to our
Apr 20, 2015
Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer
Utrecht, The Netherlands, May 20, 2015 — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, and Selexis SA, a serial innovation company with proven technologies for biologics drug discovery and Research Cell Bank (RCB) development, today
Apr 08, 2015
Merus reaches pivotal milestone in bispecific antibody collaboration with ONO PHARMACEUTICAL CO., LTD.
– Successful product lead identification underscores the strength of Merus’ platform in delivering human, full-length IgG bispecific antibodies – Utrecht, The Netherlands, 8th April 2015 – Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics, announced today that it has
Feb 04, 2015
Merus starts Phase I/II clinical trial for MCLA-128, an ADCC-enhanced bispecific antibody for solid tumors
– First patient dosed in trial with potent bispecific antibody overcoming resistance to HER2-targeted therapies – Utrecht, The Netherlands, February 4, 2015 — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced the initiation
Jan 05, 2015
After US court ruling, Merus reaffirms freedom to operate for its MeMo® transgenic mouse for therapeutic human antibodies
Posted on 5 January, 2015 Merus B.V., a leader in developing best-in-class antibody therapeutics to treat cancer patients, today announced a series of pivotal events in its litigation with Regeneron Pharmaceuticals Inc. Previously, Regeneron sued Merus accusing it of infringing U.S. Patent No.
Dec 23, 2014
J.P. Morgan Healthcare Conference
Posted on 23 December, 2014 33rd Annual J.P. Morgan Healthcare Conference, San Francisco January 12-15, 2015
Nov 03, 2014
Protein & Antibody Engineering Summit
Posted on 3 November, 2014 Merus to present at the annual Protein & Antibody Engineering Summit (PEGS), Lisbon on November 4, 2014.
Sep 18, 2014
Patent position of Merus’ MeMo® Mouse strengthened by ruling of European Patent Office
Posted on 18 September, 2014 In 2012, Regeneron was granted a European patent entitled “Methods of Modifying Eukaryotic Cells”. The patent is part of Regeneron’s IP portfolio around its VelocImmune® mouse for therapeutic human antibodies. Merus filed an opposition against this patent in June 2013,
Mar 04, 2014
ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology
Posted on 4 March, 2014 Under the terms of the agreement, ProBioGen is granting Merus the non-exclusive right to use the GlymaxX® technology to enhance the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of one of its lead products, a bispecific anti-cancer antibody.
Oct 23, 2013
Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies
Posted on 23 October, 2013 Using standard industry processes, MeMo®-derived common light chain antibodies can be manufactured in clonal cell lines to efficiently obtain full-length IgG human bispecific antibodies (branded as Biclonics™) for therapy.
Jul 01, 2013
Merus Selects Clinical Candidate for the Treatment of Acute Myeloid Leukemia (AML)
Posted on 1 July, 2013 MCLA-117 is a human, full-length IgG bispecific antibody, which activates the patient’s own immune system by simultaneously binding to the CLEC12A molecule expressed by AML tumor cells and the CD3 molecule expressed by T cells.
Jun 17, 2013
Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013
Posted on 17 June, 2013 The compound is being developed for the treatment of acute myeloid leukemia (AML), a disease with very poor long-term prognosis. MCLA-117 activates the patient’s own immune system by simultaneously binding to the CLEC12A molecule expressed by AML tumor cells and the
Mar 10, 2013
Merus Secures €31 Million in Series B Round Extension
Posted on 10 March, 2013 Johnson & Johnson Development Corporation (JJDC) joined as a new investor along with existing investors Novartis Venture Fund, Pfizer Venture Investments, Bay City Capital, LSP (Life Sciences Partners), and Aglaia Oncology Fund.
Mar 07, 2013
Merus Further Expands R&D Capacity
Posted on 7 March, 2013 Under an agreement signed with R&D service provider FairJourney Biologics, Merus will strengthen its R&D resources for selecting the most promising common light chain antibodies generated by its MeMo® transgenic mouse.
Feb 07, 2013
Merus Achieves Milestone with Novartis Option Fund
Posted on 7 February, 2013 In 2010, Merus had entered into an option agreement with the Novartis Option Fund for an exclusive license to one of Merus’ oncology programs. The deal grants the Novartis Option Fund rights to a product candidate created by the Biclonics™ and Oligoclonics™ technologies
Jan 14, 2013
OcellO and Merus Sign Agreement for Screening Bispecific Cancer Antibodies
Posted on 14 January, 2013 “This agreement builds on a successful pilot study to test the suitability of the OcellO platform for screening Merus’ therapeutic bispecific antibodies,” said Dr. Leo Price, Chief Scientific Officer at OcellO. “It aims to establish a long-term relationship between OcellO
Dec 11, 2012
Merus Appoints Setareh van Driel Shamsili as Chief Medical Officer
Posted on 11 December, 2012 Setareh van Driel Shamsili has more than 22 years of experience in general medicine, internal medicine and medical oncology. For the past 13 years, she has focused on both translational and clinical cancer research. She has more than eight years of experience in the
Oct 08, 2012
Merus announces the full validation of its MeMo(R) transgenic mouse for common light chain human antibodies
Posted on 8 October, 2012 The MeMo® mouse creates human antibody diversity using a large repertoire of human heavy chains paired with a common human light chain. “Over the last year, we have immunized MeMo® mice with half a dozen antigens and analyzed the immune response,” said Mark Throsby,
Jun 20, 2012
Merus receives EP patent covering the expression of defined antibody combinations
Posted on 20 June, 2012 Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that it has been granted the first European patent covering its Oligoclonics® technology from a patent family that already comprises 4 issued US patents.
Jun 15, 2012
Merus announces appointment of Jason Avery as Chief Business Officer
Posted on 15 June, 2012 Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that Jason Avery has been appointed as Chief Business Officer. With a professional background as Head of Business Development at Affitech A/S and Chief Business
Sep 27, 2011
Merus launches MeMo, a transgenic mouse for improved therapeutic human monoclonal antibodies
Posted on 27 September, 2011 Merus announced today that it has completed the construction of a single-light chain transgenic mouse for the generation of therapeutic human monoclonal antibodies. MeMo™ provides rapid access to large collections of high affinity antibodies for direct functional
May 16, 2011
Merus receives grant for breast cancer antibody therapy
Posted on 16 May, 2011 Utrecht, The Netherlands and Zurich, Switzerland, May 16 2011 – Merus BV and ChromaCon AG announced today the award of a EUREKA Eurostars grant with a total budget of €1.8 million to discover and develop bispecific antibodies for treatment of metastatic breast cancer.
Sep 19, 2010
Dr. Wolfgang Berthold joins Supervisory Board Merus
Posted on 19 September, 2010 Dutch biopharmaceutical company Merus announced today that Dr. Wolfgang (Wolf) Berthold has joined its Supervisory Board. “We are delighted to appoint Wolf Berthold in Merus’s Supervisory Board. He brings with him a wealth of industry and product development
Jun 02, 2010
Merus Announces Publication of the Generation of Single, Clonal Cell lines
Posted on 2 June, 2010 Merus BV today announced the April 16, 2010 online publication of data by J. de Kruif et. al., in the ‘Early View’ section of the journal Biotechnology and Bioengineering that demonstrate for the first time the feasibility of producing mixtures of human monoclonal
Jan 29, 2010
Merus closes EUR 21.7 million Series B financing and enters option agreement with the Novartis Option Fund
Utrecht, The Netherlands, January 29, 2010 – Merus, a biopharmaceutical company located in Utrecht, The Netherlands, announced today that it has closed a €21.7 million ($30.7 million) Series B financing round led by new investors the Novartis Option Fund, Pfizer Inc.
Dec 15, 2009
Merus receives EuroTransBio Grant
Posted on 15 December, 2009 Merus BV, a biopharmaceutical company focused on the discovery and development of mixtures of human therapeutic antibodies, today announced that it has received a grant worth € 0.67 million for the development of an antibody combination therapy for chronic inflammatory